## NOC: Northrop Grumman Corporation - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 3.5% below STRENGTH zone (4.0-10.0%); PEG 3.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($561.98)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Did New Missile Warning and EW Contracts Just Shift Northrop Grumman's (NOC) Investment Narrative?**
- Source: Simply Wall Street | 20251221T030906 | Bullish | Relevance: 100%
- Northrop Grumman (NOC) has recently secured significant U.S. and allied defense contracts for missile warning, space, and electronic warfare systems, reinforcing its investment thesis of sustained government demand. These wins, particularly for Space Development Agency Tracking Layer satellites, are expected to strengthen backlog growth while maintaining reliance on large U.S. programs. The company's narrative projects substantial revenue and earnings growth by 2028, suggesting a significant upside to its current price despite potential risks from future budget shifts.

**2. Northrop Grumman (NOC): Taking Stock of Valuation After a Strong Year-to-Date Share Price Run**
- Source: Simply Wall Street | 20251220T010811 | Somewhat-Bullish | Relevance: 100%
- Northrop Grumman (NOC) has seen its stock price rise by 21% year-to-date, outperforming many defense peers, and leading to questions about its current valuation. While a "narrative" valuation suggests the stock is 14.2% undervalued due to growth in advanced systems and rocket motor capacity, a more cautious Simply Wall St DCF model indicates it might be slightly overvalued. Investors are faced with deciding which valuation perspective is more compelling given the company's strong performance and future prospects.

**3. Northrop Grumman receives $50 million contract modification for LITENING**
- Source: Investing.com | 20251222T224034 | Bullish | Relevance: 100%
- Northrop Grumman Systems Corp. secured a $50 million contract modification for the LITENING CATP program, bringing the total contract value to $1.36 billion. The work will be performed at the companyâ€™s Rolling Meadows, Illinois facility, with completion expected by December 31, 2025, though delivery orders may extend to 2029. The modification, identified as P00033 to previously awarded contract FA8540-19-D-0001, does not obligate immediate funding and excludes Foreign Military Sales.

**4. Northrop Grumman awarded $264.87M Defense Logistics Agency contract modification**
- Source: MSN | 20251222T040854 | Bullish | Relevance: 100%
- Northrop Grumman has been awarded a $264.87 million contract modification by the Defense Logistics Agency. This modification is related to the previous contract for parts and materials for the B-2 platform. The contract will run through September 30, 2029.

**5. 14 Best Aerospace and Defense Stocks to Buy According to Wall Street Analysts**
- Source: Insider Monkey | 20251220T043000 | Somewhat-Bullish | Relevance: 64%
- This article identifies 14 top aerospace and defense stocks favored by Wall Street analysts. It highlights TransDigm Group Incorporated (NYSE: TDG) as a strong buy, citing its robust business model, growth potential in commercial aerospace and defense, and strategic focus on M&A. The company's ability to generate long-term value through strong pricing power and disciplined execution is also emphasized.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Alembic Global | $662 | $0 | 0% |
| 2025-12-12 | Citigroup | $654 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Alembic Global | up | Overweight |
| 2025-12-12 | Citigroup | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($0.08M) |
| Sells | 2 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.5% (+0.8%)
- State Street Corpora: 9.3% (-1.6%)
- Capital Internationa: 8.2% (-1.7%)
- Blackrock Inc.: 6.9% (+1.0%)
- JPMORGAN CHASE & CO: 3.9% (+91.5%)

### Key Risks

1. Valuation stretched: PEG 3.6x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.62 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 26%). Balance sheet: $1.3B free cash flow. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $83.7B |
| Beta | 0.05 |
| 52W Range | $426.24 - $640.90 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.62 |
| Forward P/E | 20.3 |
| Current P/E | 22.4 |
| YoY Growth | 10.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.6% to 3.5% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. AM_20 at 4.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.21), confirming momentum. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +F0L (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.55% (CS: 76) | Neutral |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | 3.21 | Bullish |
| vs SMA20 | 1.041x | Above |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.079x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $584.54
- **Stop Loss:** $561.98 (3.9% risk)
- **Target:** $607.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $22,797.06
- **Portfolio %:** 22.80%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-29 (Est: $6.95)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.46 | $7.67 | +18.8% |
| 2025Q2 | $6.80 | $8.15 | +19.9% |
| 2025Q1 | $6.26 | $3.32 | -47.0% |
| 2024Q4 | $6.35 | $6.39 | +0.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*